Asia Pacific Drug Discovery Informatics Market Size, Share & Trends Analysis Report By Application (Drug Discovery, and Drug Development), By Function, By End User, By Country and Growth Forecast, 2024 - 2031

The Asia Pacific Drug Discovery Informatics Market would witness market growth of 10.9% CAGR during the forecast period (2024-2031).

The China market dominated the Asia Pacific Drug Discovery Informatics Market by Country in 2023 and would continue to be a dominant market till 2031; thereby, achieving a market value of $443.5 million by 2031. The Japan market is registering a CAGR of 10.2% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 11.6% during (2024 - 2031).



Rising demand for combination therapies is also leading to an increased demand for drug discovery platforms. Combination therapies often requires the integration and analysis of diverse datasets, including genomic data, clinical data, and drug response data, to identify synergistic drug combinations and optimize treatment regimens. Drug repurposing drives the drug discovery informatics market by leveraging existing knowledge, data, and resources to identify new therapeutic opportunities for existing drugs or compounds.

Additionally, during health crises such as pandemics, there is an urgent need to develop effective therapeutics and vaccines to combat the spread of infectious diseases. Communicable diseases such as malaria, tuberculosis, and HIV/AIDs are increasingly widespread. However, with a rising demand in the drug discovery informatics market, certain factors hinder its growth. High licensing fees and royalties may deter organizations from adopting informatics platforms or restrict their ability to scale up informatics initiatives.

Pharmaceutical companies in Asia, particularly in countries like China, India, and South Korea, are increasing their investment in research and development. This includes investment in informatics platforms and technologies to streamline drug discovery processes, enhance efficiency, and accelerate the development of new drugs. As per China.org.cn, China's pharmaceutical firms saw their combined business revenue climb 18.7 percent year on year in 2021, the highest growth rate in five years. Companies in this sector together raked in 3.37 trillion yuan (about 502 billion U.S. dollars) in revenue in 2020. In 2021, they generated a total of 708.75 billion yuan in profits. Thus, as the expansion of the pharmaceutical sector is expected to continue, Asia will continue to be the key player in the drug discovery informatics market.

Based on Application, the market is segmented into Drug Discovery, and Drug Development. Based on Function, the market is segmented into Sequencing & Target Data Analysis, Molecular Modelling, Library & Database Preparation, Docking, and Others. Based on End User, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

List of Key Companies Profiled

• Oracle Corporation
• Accenture PLC
• Thermo Fisher Scientific, Inc.
• Boehringer Ingelheim International GmbH
• Infosys Limited
• Charles River Laboratories International, Inc.
• Agilent Technologies, Inc.
• Illumina, Inc.
• Certara, Inc.
• Jubilant Pharmova Limited

Market Report Segmentation

By Application

• Drug Discovery
• Drug Development

By Function

• Sequencing & Target Data Analysis
• Molecular Modelling
• Library & Database Preparation
• Docking
• Others

By End User

• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations
• Others

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific